Literature DB >> 23983943

SSRI-induced coagulopathy: is it reality?

Riyaz Siddiqui, Sushil Gawande, Tanaji Shende, Rahul Tadke, Sudhir Bhave, Vivek Kirpekar.   

Abstract

OBJECTIVES: To study the effect of escitalopram and fluoxetine on coagulation profile in patients with major depression.
METHOD: This was a prospective, open-label, single-centre study in 40 patients diagnosed with major depressive disorder. The patients were diagnosed using Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria. Twenty patients receiving escitalopram 10 mg per day and 20 patients receiving fluoxetine 20 mg per day participated in the study and were followed up for 3 months. Coagulation parameters - bleeding time, clotting time, platelet count, prothrombin time and partial thromboplastin kaolin time - were evaluated at baseline and after 3 months.
RESULTS: At the end of 3 months, a significant increase in bleeding time was seen in patients receiving fluoxetine, but within the normal range. No rise was seen in the group given escitalopram.
CONCLUSION: In patients with depression, fluoxetine increases bleeding time whereas escitalopram has no effect on coagulation profile. However, both the drugs can be used safely for long-term treatment.

Entities:  

Keywords:  SSRI; coagulopathy; escitalopram; fluoxetine

Year:  2011        PMID: 23983943      PMCID: PMC3736913          DOI: 10.1177/2045125311423781

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  15 in total

1.  Citalopram-induced bleeding due to severe thrombocytopenia.

Authors:  Frank Andersohn; Christine Konzen; Elisabeth Bronder; Andreas Klimpel; Edeltraut Garbe
Journal:  Psychosomatics       Date:  2009 May-Jun       Impact factor: 2.386

2.  Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis.

Authors:  S Wessinger; M Kaplan; L Choi; M Williams; C Lau; L Sharp; M D Crowell; A Keshavarzian; M P Jones
Journal:  Aliment Pharmacol Ther       Date:  2006-04-01       Impact factor: 8.171

3.  Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.

Authors:  D Layton; D W Clark; G L Pearce; S A Shakir
Journal:  Eur J Clin Pharmacol       Date:  2001-05       Impact factor: 2.953

4.  Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence.

Authors:  M B Lake; B Birmaher; S Wassick; K Mathos; A K Yelovich
Journal:  J Child Adolesc Psychopharmacol       Date:  2000       Impact factor: 2.576

Review 5.  Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review.

Authors:  Rajamannar Ramasubbu
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

Review 6.  [SSRI - treatment and bleeding. What risks do we take?].

Authors:  T Strubel; A Birkhofer; G Mössmer; H Förstl
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

7.  Maternal selective serotonin reuptake inhibitor intake does not seem to affect neonatal platelet function tests.

Authors:  A Maayan-Metzger; J Kuint; A Lubetsky; Boris Shenkman; R Mazkereth; G Kenet
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

Review 8.  SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?

Authors:  Susanne O Dalton; Henrik T Sørensen; Christoffer Johansen
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.

Authors:  Susanne Oksbjerg Dalton; Christoffer Johansen; Lene Mellemkjaer; Bente Nørgård; Henrik Toft Sørensen; Jørgen H Olsen
Journal:  Arch Intern Med       Date:  2003-01-13

10.  [Ecchymosis associated with the use of fluoxetine: case report].

Authors:  Hasan Mirsal; Ayhan Kalyoncu; Ozkan Pektaş
Journal:  Turk Psikiyatri Derg       Date:  2002
View more
  4 in total

1.  Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs.

Authors:  Donatella Marazziti; Federico Mucci; Beniamino Tripodi; Manuel Glauco Carbone; Alessia Muscarella; Valentina Falaschi; Stefano Baroni
Journal:  Clin Neuropsychiatry       Date:  2019-04

2.  Association Between Bipolar Disorder or Schizophrenia and Oral Anticoagulation Use in Danish Adults With Incident or Prevalent Atrial Fibrillation.

Authors:  Morten Fenger-Grøn; Claus Høstrup Vestergaard; Anette Riisgaard Ribe; Søren Paaske Johnsen; Lars Frost; Annelli Sandbæk; Dimitry S Davydow
Journal:  JAMA Netw Open       Date:  2021-05-03

3.  The Extrinsic Coagulation Pathway: a Biomarker for Suicidal Behavior in Major Depressive Disorder.

Authors:  Yongtao Yang; Jin Chen; Chengyu Liu; Liang Fang; Zhao Liu; Jing Guo; Ke Cheng; Chanjuan Zhou; Yuan Zhan; Narayan D Melgiri; Liang Zhang; Jiaju Zhong; Jianjun Chen; Chenglong Rao; Peng Xie
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

4.  Escitalopram-induced epistaxis: A case report.

Authors:  Sumayah A AlJhani
Journal:  J Taibah Univ Med Sci       Date:  2021-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.